Sanofi faces stock decline as CEO change announced, market cap of $113.6B, shares down 4.5%, near 52-week low.
Sanofi SA (NASDAQ: SNY) shares are experiencing a decline in the premarket session on Friday due to leadership changes amidst ongoing issues in its drug pipeline. The French drugmaker, with a market cap of approximately $113.6 billion, closed 4.5% lower on Thursday, moving closer to the lower end of its 52-week range of $44.62-$60.12. The departure of CEO Paul Hudson was announced by the board, with Belén Garijo set to succeed him. Hudson's last day as CEO is scheduled for February 17, and Garijo will assume the role after the Annual General Meeting on April 29. Sanofi aims to strengthen its strategy and innovation capacity, particularly in Research & Development. In the fourth quarter of 2025, Sanofi saw a significant 32.2% increase in sales of its leading drug, Dupixent, amounting to 4.2 billion euros.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments